Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 3, 2000, Pages 1043-1048

  Ahrén, Bo ^a,d   Holst, Jens Juul ^b   Efendic, Suad ^c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; INSULIN; PANCREAS; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; SINCALIDE;

EID: 0034454424     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.3.1043     Document Type: Article

References (42)

1. Cholecystokinin: A hormone and neurotransmitter
2. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs
3. Cholecystokinin (CCK)-4 and CCK-8 stimulate islet hormone secretion in vivo in the pig
4. Effects of two cholecystokinin variants, CCK-39 and CCK-8 on basal and stimulated insulih secretion
5. Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice
6. Effects of cholecystokinin, gastric inhibitory polypeptide and secretin on insulin and glucagon secretion in rats
7. Cholecystokinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: Studies on the structure-activity relationship
8. Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718
9. Cholecystokinin-stimulated insulin secretion and protein kinase C in rat pancreatic islets
10. Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718, a specific inhibitor of CCK-receptor binding
11. Physiological concentrations of cholecystokinin stimulate amino-acid induced insulin release in humans
12. Regulation of pancreatic endocrine function by cholecystokinin: Studies with MK-329, a nonpeptide cholecystokinin receptor antagonist
13. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide on basal and meal-stimulated pancreatic hormone secretion in man
14. Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man
15. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8
16. Insulin release in fasting man induced by impure but not by pure preparations of cholecystokinin
17. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers
18. Innervation of the pancreas by substance P, enkephalin, vasoactive intestinal polypeptide and gastrin/CCK immunoreactivity
19. Neural regulation of pancreatic hormone secretion by the C-terminal tetrapeptide of CCK
20. Cholecystokinin and the regulation of insulin secretion
21. β-cells in type II diabetes mellitus
22. Insulin release in type 2 diabetes mellitus
23. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance
24. Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: Evidence for a role for CCK in regulating postprandial hyperglycemia
25. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus
26. Glucagon-like peptide I (GLP-1): A gut hormone of potential interest in the treatment of diabetes
27. The incretin notion and its relevance to diabetes
28. Role of hyperglucagonemia in maintenance of increased rate of hepatic glucose output in type II diabetes
29. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics
30. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
31. Radioimmunoassay for gastric inhibitory polypeptide
32. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man
33. Insulin and C-peptide secretory responses to glucagon in man: Studies on the dose-response relationships
34. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice
35. Evidence for a functional role of the cholecystokinin B/gastrin receptor in the human fetal and adult pancreas
36. Regulation of gastric emptying in humans by cholecystokinin
37. Cholecystokinin in the inhibition of gastric secretion and gastric emptying in humans
38. Effect of cholecystokinin on gastric motility in humans
39. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans
40. Role of cholecystokinm in the regulation of liquid gastric emptying and gastric motility in humans: Studies with the CCK antagonist loxiglumide
41. Phsyiological role for cholecystokinin in reducing postprandial hyperglycemia in humans